This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petersen, P. M. Articles by von der Maase, H. Search for Related Content PubMed PubMed Citation Articles by Petersen, P. M. Articles by von der Maase, H. Social Bookmarking                            What's this?

Effect of Graded Testicular Doses of Radiotherapy in Patients Treated for Carcinoma-In-Situ in the Testis

From the Departments of Growth & Reproduction and Oncology, Finsencenter, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Department of Biostatistics, University of Copenhagen; Department of Oncology, Herlev University Hospital, Herlev; and Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Address reprint requests to Peter Meidahl Petersen, MD, Department of Growth and Reproduction, Copenhagen University Hospital, Herlev, 9 Blegdamsvej, R54B1, Copenhagen 2730, Denmark; email: pmp{at}post11.tele.dk

PURPOSE: To determine the effect of radiotherapy in doses 14 to 20 Gy on eradication of carcinoma-in-situ (CIS) testis and on the Leydig cell function.

PATIENTS AND METHODS: Forty-eight patients presented with unilateral testicular germ cell cancer and CIS of the contralateral testis. The CIS-bearing testis was treated with daily irradiation doses of 2 Gy, 5 days a week, to a cumulative dose of 20 Gy (21 patients), 18 Gy (three patients), 16 Gy (10 patients), and 14 Gy (14 patients).

RESULTS: All patients treated at dose levels 20 Gy to 16 Gy achieved histologically verified complete remission without signs of recurrence of CIS after an observation period of more than 5 years. One of 14 patients treated at dose level 14 Gy had a relapse of CIS 20 months after irradiation. Leydig cell function was examined before and regularly after radiotherapy in 44 of 48 patients. The levels of testosterone were lower after radiotherapy than before. Testosterone showed a stable decrease for more than 5 years after treatment (3.6% per year) without dose dependency. The levels of luteinizing hormone and follicle-stimulating hormone were increased after radiotherapy. The need of androgen substitution therapy was similar at all dose levels.

CONCLUSION: Testicular irradiation is a safe treatment at dose level 20 Gy (10 x 2 Gy). Decrease of dose to 14 Gy (7 x 2 Gy) might lead to risk of relapse of CIS. Impairment of hormone production without clinically significant dose dependency is seen in the dose range 14 to 20 Gy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. D. Fossa Second Cancers among Survivors of Testicular Cancer: The Emerging Picture ASCO Educational Book, January 1, 2008; 2008(1): 423 - 426. [Abstract] [Full Text] [PDF]

				D. J. Brenner, I. Shuryak, S. Russo, and R. K. Sachs Reducing Second Breast Cancers: A Potential Role for Prophylactic Mammary Irradiation J. Clin. Oncol., November 1, 2007; 25(31): 4868 - 4872. [Full Text] [PDF]

				R. Sivakumar, P. B. Sivaraman, N. Mohan-Babu, I. M. Jainul-Abideen, P. Kalliyappan, and K. Balasubramanian Radiation Exposure Impairs Luteinizing Hormone Signal Transduction and Steroidogenesis in Cultured Human Leydig Cells Toxicol. Sci., June 1, 2006; 91(2): 550 - 556. [Abstract] [Full Text] [PDF]

				S. D. Fossa, J. Chen, S. J. Schonfeld, K. A. McGlynn, M. L. McMaster, M. H. Gail, and L. B. Travis Risk of Contralateral Testicular Cancer: A Population-based Study of 29 515 U.S. Men J Natl Cancer Inst, July 20, 2005; 97(14): 1056 - 1066. [Abstract] [Full Text] [PDF]

				H. J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) Ann. Onc., September 1, 2004; 15(9): 1377 - 1399. [Abstract] [Full Text] [PDF]

				S. D. Fossa, N. Aass, A. Heilo, G. Daugaard, N. E. Skakkebaek, A. E. Stenwig, J. M. Nesland, L. H. J. Looijenga, and J. W. Oosterhuis Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy Ann. Onc., September 1, 2003; 14(9): 1412 - 1418. [Abstract] [Full Text] [PDF]

				J. Classen and K.-P. Dieckmann Radiotherapy of Carcinoma-In-Situ of the Testis J. Clin. Oncol., August 15, 2002; 20(16): 3559 - 3560. [Full Text] [PDF]